Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Bayer

Status: Completed

Conditions: Prostate Cancer

Treatments: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Study type: Observational

Funder types: Industry

Identifiers

NCT02518698

18273

Details and patient eligibility

About

The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.

Enrollment: 1,163 patients

Sex: Male

Ages: 55 to 88 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period
• Members age ≥ 55 to 89 years at index
• Medicare members with medical and pharmacy coverage; and
• Continuously enrolled during the pre- and post-index periods.

Exclusion criteria

• Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other metastases (ICD-9 198.x)) before the index date; and
• Members age ≥ 89 years of age at index date

Trial design

1,163 participants in 1 patient group

Cohort 1 / Treatment patterns

Description:

Patients with castrated resistant prostate cancer and bone metastases

Treatment:

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)